netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Spironolactone found 15 matches

Open monograph to display formulary status BNF Category
  Spironolactone Cardiovascular system - Aldosterone antagonists - 02.02.03
  Spironolactone Endocrine system - Gender dysphoria - 06.04.04
  Spironolactone Skin - Oral preparations for acne - 13.06.02
  Spironolactone and chlorothiazide capsules Cardiovascular system - Potassium-sparing diuretics with other diuretics - 02.02.04
  Eplerenone Cardiovascular system - Aldosterone antagonists - 02.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.02.03)
link in subsection MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05)
link in subsection MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05.01)
link in subsection MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05.02)
link in subsection MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 (02.05.05.03)
link in drug section MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.02.03)
link in subsection MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05.03)
link in subsection MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05.02)
link in subsection MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05)
link in subsection MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia. (02.05.05.01)


 

netFormulary